Novavax (NVAX) Tops Q2 EPS by 12c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Novavax Reports Second Quarter 2020 Financial and Operational Results
August 10, 2020 4:03 PM EDTAnnounced Positive Phase 1 data of Phase 1/2 clinical trial of NVX-CoV2373
Secured $2 billion in funding for global coronavirus vaccine program through CEPI, DoD, and OWSExpanded large scale global manufacturing capacity through acquisition and partneringCompany to host conference call today at 4:30 p.m. ET
GAITHERSBURG, Md., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational... More
